ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCERecallNotable

FDA Class III Recall: Elevate Oral Care's Sodium Fluoride Product Pulled Due to Label Mix-Up

PS
Priya SubramaniamView Profile →
Intelligence Analyst
EXECUTIVE SUMMARY

Elevate Oral Care has completed a Class III recall (D-0658-2024) of its Just Right 5000, 1.1% Sodium Fluoride, Candy Apple Flavor product. Initiated on August 20, 2024, the voluntary recall addressed a critical label mix-up affecting 120 direct customers nationwide. This event underscores the persistent risk of packaging errors in pharmaceutical supply chains, demanding robust quality control protocols from manufacturers and vigilant oversight from procurement teams.

FDA Action: Elevate Oral Care Initiates Class III Recall for Sodium Fluoride Product

On August 20, 2024, Elevate Oral Care initiated a voluntary, firm-initiated recall (D-0658-2024) for its dental therapeutic product, Just Right 5000, 1.1% Sodium Fluoride, Candy Apple Flavor. This action, classified by the FDA on September 12, 2024, as a Class III recall, was prompted by a critical label mix-up. For procurement directors and regulatory affairs heads, a Class III classification indicates that the product is unlikely to cause adverse health consequences, but the deviation from regulatory standards still represents a significant quality control failure. The specific affected lot identified was #G073DC, with an expiration date of March 31, 2026. This incident underscores the importance of rigorous quality assurance protocols in packaging operations, as even seemingly minor labeling errors can trigger extensive recalls and impact supply chain reliability. Businesses sourcing oral care pharmaceuticals must ensure their suppliers implement robust verification steps to prevent such discrepancies, safeguarding both product integrity and patient safety.

Elevate Oral Care's Product Scope and Distribution Footprint

The recalled product, Just Right 5000, is a 1.1% Sodium Fluoride formulation, presented in a Candy Apple Flavor, with a net weight of 3.4oz (97g) and designated for prescription use (Rx Only). Its National Drug Code (NDC) is 57511-002-1. The product is manufactured for Elevate Oral Care, LLC, based in West Palm Beach, Florida, specifically at 346 Pike Rd, Suite 5, West Palm Beach, FL 33411, with the note that it is made in the U.S.A. with an imported pump. The distribution pattern for this specific lot was confined to 120 direct customers across the Nationwide US, with no foreign distribution or sales to the Department of Defense (DOD) or Veterans Affairs (VA). This contained distribution limits the immediate global supply chain impact, but procurement teams must still assess the implications for domestic sourcing. Understanding the manufacturing origin and component sourcing, such as the imported pump, is crucial for supply chain VPs to identify potential points of vulnerability and ensure comprehensive supplier due diligence extends beyond the primary manufacturer to critical component providers.

Regulatory Resolution and Industry Implications for Oral Care Sourcing

The FDA officially terminated the recall (D-0658-2024) on August 5, 2025, signaling that Elevate Oral Care has successfully addressed the labeling issue and removed affected products from the market. This termination provides clarity for business development executives and supply chain VPs regarding the product's current status and the company's compliance trajectory. While this specific event was a Class III recall, the broader regulatory environment demands constant vigilance. Recent parallel events, such as Essential Wellness Pharma's Class II recall for sterility failures or the FDA hearing impacting Amgen's Tavneos, highlight the diverse and persistent regulatory challenges across the life sciences sector. For procurement directors, this Elevate Oral Care recall serves as a reminder that even voluntary, firm-initiated actions for seemingly minor issues like label mix-ups can disrupt supply and necessitate immediate response. Establishing robust supplier qualification programs that include regular audits of labeling and packaging processes is paramount to mitigating future risks and ensuring uninterrupted supply of critical oral care products.

ChemLifeIntel analysis · Priya Subramaniam. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

Elevate Oral Care
company hub
Open company hub
Sodium Fluoride 0.02 (0.009 W/V Fluoride Ion)
molecule hub
Open molecule hub